Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders

Inclusion Criteria:

• The increased risk of psychosis includes either a symptomatic "ultra high-risk"stage of the Structured Interview for Psychosis-Risk Syndromes or the "CognitiveDisturbances" risk criterion of the Schizophrenia Proneness Instrument - Childrenand Youth and Adult versions

• ages 16 to 40

• Presence of a written informed consent from the patient and, if applicable, thelegal guardian.

Exclusion Criteria:

• manifest psychosis according to the definition of the Structured Interview forPsychosis-Risk Syndromes (according to the PRONIA-study) (At least one P-syndromewith a rating of 6 on a daily frequency and for a period of more than one week)

• Lack of capacity to give consent (the patient lacks the capacity to consent if theindividual case with regard to the specific treatment measure is excluded. Only whenthe physician has concrete indications that the patient's capacity to consent may belacking, he may and must must examine it. Mental disorders (e.g. delirium, dementia,psychosis, mania, depression) or cognitive impairments can have an influence on thecapacity to consent. Indications for doubts of a ability to give informed consentexist if the physician has the impression that the patient is not able to understandthe provided patient information and is not able to reproduce essential informationabout the study in his or her own words and is not aware of the possibleconsequences of the proposed measures

• Severe suicidality during the recruitment phase (CDSS items 8 ≥2)

• A current or past neurological disease of the brain.

• a current or past known somatic disease that potentially affects the structure orfunction of the brain

• Antipsychotic medication in the indication treatment of psychotic symptoms for >30days (cumulative number of days) at or above the starting dose for psychosisaccording to the current German Association for Psychiatry, Psychotherapy andPsychosomatics (DGPPN) S3 guidelines.

• an antipsychotic medication in the indication treatment of psychotic symptoms in the 3 months prior to the initial examination (regardless of the duration of use) at orabove the starting dose for psychosis according to the current DGPPN S3 guidelines

• An inadequate level of hearing for neurocognitive testing

• a current or past head trauma with unconsciousness (>5 min).

• a current or past alcohol dependence (ICD-10 F10.x)

• A current polytoxicomania (multiple substance dependence) or polytoxicomania in thepast 6 months (ICD-10 F19.x)

• Presence of medical reasons that contraindicate performance of an MRI

• Insufficient language skills to understand the indication and the purpose of theintended examinations and interventions

• stationary accommodation against the patient's will